Effectiveness of Renal Denervation in Patients with Resistant Hypertension Using Certified Equipment (Results of 1-Year Follow-Up)

Yu.M. Sirenko, O.L. Rekovets, Yu.M. Sokolov, A.S. Dobrohod


Completed controlled trials have shown the safety but different effectiveness of renal denervation (RDN) in patients with resistant arterial hypertension (AH). We have carried out RDN in 8 patients. The average age of patients was 52.13 ±
± 3.88 years (40–66), mean duration of AH — 16.75 ± 2.17 (12–25) years. On admission to hospital institute, blood pressure (BP) level was 181.25/106.88 ± 4.3/4.0 mmHg (160–200/85–120 mmHg), heart rate (HR) — 70.63 ± 3.03 bpm. Optimization of treatment in a hospital in these patients led to a significant decrease in BP to 156.88/95.00 ± 2.98 mmHg (150–165/85–100 mmHg) and HR — 68.88 ± 3.28 bpm. The number of antihypertensive drugs was an average of 5.5 per patient. In ambulatory blood pressure monitoring (ABMP) on the stage of therapy optimization, the average systolic BP (SBP24) was 149.16 ± 5.40 mmHg, and diastolic (DBP24) — 86.98 ± 5.08 mmHg. Average daily heart rate (HR24) was 70.12 ± ± 2.94 bpm. All patients underwent the procedure well.
Mean reduction in the average daily BP (SBP/DBP) was in the dynamics at the stage of 7 days, 1, 6 and 12 months, respectively, –15.73/–8.52 mmHg, –11.45/–6.06 mmHg, –10.70/
–13.68 mmHg and –17.91/–13.88 mmHg. HR24 was not significantly changed. Reducing daytime SBP/DBP in the dynamics at the stages of 7 days, 1, 6 and 12 months was –14.79/–5.64,
–16.55/–5.60, –12.29/–12.79 and –20.45/–13.62 mmHg, respectively. Dynamics of decrease in nocturnal SBP/DBP at the stages of 7 days, 1, 6 and 12 months was –15.03/–8.42, –10.64/
–4.57, –9.23/–12.38 and –19.39/–14.84 mmHg, respectively. In SBP24 ≥ 160 mmHg 12 months after RDN we observed the most significant decrease in the average daily BP –30.5/–18.9 mmHg. In SBP24 ≥ 140 mmHg and < 160 mmHg 12 months after the procedure, reduction of SBP24/DBP24 was –20.1/–18.0 mmHg. When SBP24 < 140 mmHg, significant changes in BP reduction were not detected. Mean reduction in office BP was in the dynamics at the stages of 7 days, 1, 6 and 12 months, respectively, –14.38/–5.63 mmHg, –9.02/–10.71 mmHg, +3.12/–8 mmHg
and –7.88/–5.0 mmHg. Office heart rate did not change.
Estimated creatinine clearance level determined by Cockcrof- Gault equation was not significantly changed in any patient. Thus, the application of RDN in patients with resistant AH is safe and recommended only in patients with SBP140 mmHg and above, according to ABPM. Mandatory use of ABMP for selection and effective control after RDN is recommended.


resistant hypertension; renal denervation; ambulatory blood pressure monitoring


Доброход Г.С. Власний досвід відбору хворих для проведення ниркової денервації // Артеріальна гіпертензія. — 2014. — № 3. — С. 45-48.

Azizi M., Steichen O., Frank M., Bobrie G., Plouin P., Sapoval M. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension // Eur. J. Vasc. Endovasc. Surg. — 2012. — Vol. 43(3). — P. 293-299.

Banegas J.R., Messerli F.H., Waeber B., Rodriguez-Artalejo F., de la Sierra A., Segura J. et al. Discrepancies between office and ambulatory blood pressure: clinical implications // Am. J. Med. — 2009. — Vol. 122. — P. 1136-1141.

Bhatt D.L., Kandzari D.E., O’Neill W.W., D’Agostino R., Flack J.M., Katzen B.T., Leon M.B., Liu M., Mauri L., Negoita M., Cohen S.A., Oparil S., Rocha-Singh K., Townsend R.R., Bakris G.L.; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension // N. Engl. J. Med. — 2014. — Vol. 370(15). — P. 1393-401.

Bakris G.L., Townsend R.R., Liu M., Cohen S.A., D’Agostino R., Flack J.M., Kandzari D.E., Katzen B.T., Leon M.B., Mauri L., Negoita M., O’Neill W.W., Oparil S., Rocha-Singh K., Bhatt D.L.; SYMPLICITY HTN-3 Investigators. Impact of Renal Denervation on 24-hour Ambulatory Blood Pressure: Results from SYMPLICITY HTN-3 // J. Am. Coll. Cardiol. — 2014 May 17.

Böhm M., Linz D., Urban D., Mahfoud F., Ukena C. Renal sympathetic denervation: applications in hypertension and beyond // Nat. Rev. Cardiol. — 2013. — Vol. 10(8). — P. 465-476.

Böhm M., Linz D., Ukena C., Esler M., Mahfoud F. Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond? // Circ. Res. — 2014 — Vol. 115(3). — P. 400-409.

Burton R.F. Estimating body surface area from mass and height: theory and the formula of Du Bois and Du Bois // Ann. Hum. Biol. — 2008. — Vol. 35(2). — P. 170-184.

Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Hypertension. — 2008. — Vol. 51. — P. 1403-1419.

Di Bona G.F., Esler M. Translational medicine: the antihypertensive effect of renal denervation //Am. J. Physiol. Regul. Integr. Comp. Physiol. — 2010. — Vol. 298. — P. R245-R253.

Egan B.M., Zhao Y., Axon R.N., Brzezinski W.A., Ferdinand K.C. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008 // Circulation. — 2011. — Vol. 124. — P. 1046-1058.

Hayek S.S., Abdou M.H., Demoss B.D., Legaspi J.M., Veledar E., Deka A., Krishnan S.K., Wilmot K.A., Patel A.D., Kumar V.R., Devireddy C.M. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients // Am. J. Hypertens. — 2013. — Vol. 26(12). — P. 1452-1458.

Hansen J.M., Abildgaard U., Fogh-Andersen N., Kanstrup I.L., Bratholm P., Plum I. et al. The transplanted human kidney does not achieve functional reinnervation // Clin. Sci. (Lond). — 1994. — Vol. 87. — P. 13-20.

Kannan S., Mahadevan S., Ramji B., Jayapaul M., Kumaravel V. LDL-cholesterol: Friedewald calculated versus direct measurement-study from a large Indian laboratory database // Indian J. Endocrinol. Metab. — 2014. — Vol. 18(4). — P. 502-504.

Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study // Lancet. — 2009. — Vol. 373. — P. 1275-281.

Mancia G., Schmieder R.E., Redon J., Grassi G., Kjeldsen S.E., Narkiewicz K., Parati G., Ruilope L., van de Borne P., Tsioufis C; European Society of Hypertension. Updated ESH position paper on interventional therapy of resistant hypertension // EuroIntervention. — 2013. — Vol. 9, Suppl. — R: R58-66.

Mahfoud F., Cremers B., Janker J., Link B., Vonend O., Ukena C., Linz D., Schmieder R., Rump L.C., Kindermann I., Sobotka P.A., Krum H., Scheller B., Schlaich M., Laufs U., Böhm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension // Hypertension. — 2012. — Vol. 60(2). — P. 419.

Papademetriou V., Tsioufis C.P., Sinhal A., Chew D.P. Meredith I.T., Malaiapan Y., Worthley M.I., Worthley S.G. Catheter-Based Renal Denervation for Resistant Hypertension: 12-Month Results of the EnligHTN I First-in-Human Study Using a Multielectrode Ablation System // Hypertension. — 2014. — Vol. 64(3). — P. 565-572.

Schlaich M.P., Sobotka P.A., Krum H., Whitbourn R., Walton A., Esler M.D. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept // Hypertension. — 2009. — Vol. 54. — P. 1195-1201.

Schuck O., Marusova L., Lanska V. Use of the Cocroft and Gault formula for evaluation of 24-hour urinary excretion of electrolytes // Bratisl. Lek. Listy. — 1999. — Vol. 100(8). — P. 422-425.

Simplicity HTN-1 Investigators 2011. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months // Hypertension. — 2011. — Vol. 57. — P. 911-17.

Simplicity HTN-2 Investigators, Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial // Lancet. — 2010. — Vol. 376. — P. 1903-1909.

Stea F., Bozec E., Millasseau S., Khettab H., Boutouyrie P., Laurent S. Comparison of the Complior Analyse device with Sphygmocor and Complior SP for pulse wave velocity and central pressure assessment // J. Hypertens. — 2014. — Vol. 32(4). — P. 873-880.

Zhang Y., Zhang X., Liu L., Zanchetti A. Is a systolic blood pressure target < 140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial // Eur. Heart J. — 2011. — Vol. 32. — P. 1500-1508.

Worthley S.G., Tsioufis C.P., Worthley M.I., Sinhal A., Chew D.P., Meredith I.T., Malaiapan Y., Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial // Eur. Heart J. — 2013. — Vol. 34(28). — P. 2132-2140.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта